SCHEMBL31369404

SCHEMBL31369404

N[C@H](Cc1c[nH]c2ccncc12)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.66
KDM4E B2RXH2 3/20 0.66
MAPT P10636 3/20 0.66
LMNA P02545 2/20 0.66
TSHR P16473 2/20 0.66
BLM P54132 2/20 0.66
PMP22 Q01453 2/20 0.66
MEN1 O00255 2/20 0.66
MPO P05164 1/20 0.66
HIF1A Q16665 1/20 0.66
CYP3A4 P08684 2/20 0.61
HSD17B10 Q99714 2/20 0.61
ALDH1A1 P00352 1/20 0.61
HTR1A P08908 1/20 0.61
ADORA3 P0DMS8 1/20 0.61
ALOX15 P16050 1/20 0.61
NFKB1 P19838 1/20 0.61
HTR2A P28223 1/20 0.61
HTR2C P28335 1/20 0.61
SLC6A4 P31645 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31267234 1.00 KMT2A (0.66) KMT2AKDM4EMAPTLMNATSHR
SCHEMBL31267200 1.00 KMT2A (0.66) KMT2AKDM4EMAPTLMNATSHR
SCHEMBL25356181 1.00 KMT2A (0.66) KMT2AKDM4EMAPTLMNATSHR
SCHEMBL17337919 1.00 KMT2A (0.66) KMT2AKDM4EMAPTLMNATSHR
Water SCHEMBL8021055 0.99 KMT2A (0.64) KMT2AKDM4EMAPTLMNATSHR
SCHEMBL7016302 0.89 KMT2A (0.66) KMT2AKDM4EMAPTLMNATSHR
SCHEMBL1897795 0.89 KMT2A (0.66) KMT2AKDM4EMAPTLMNATSHR
SCHEMBL31370083 0.89 KMT2A (0.66) KMT2AKDM4EMAPTLMNATSHR
SCHEMBL26014415 0.86 HTR6 (0.59) KMT2AKDM4EMAPTLMNATSHR
Dl-Tryptophan SCHEMBL28121864 0.81 KDM4E (0.84) KMT2AKDM4EMAPTLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2024-12-05 US claimed
US-20250222146-A1 Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof RAYZEBIO, INC. (US) 2025-07-10 US disclosed
WO-2025137441-A1 RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF RAYZEBIO, INC. (US) 2025-06-26 WO disclosed
WO-2025137443-A1 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING SOMATOSTATIN RECEPTORS AND USES THEREOF RAYZEBIO, INC. (US) 2025-06-26 WO disclosed
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2024-12-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250222146-A1 Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof SSTR2, SSTR4, SSTR5 KMT2A 1730/4885KDM4E 3869/4885MAPT 3475/4885
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES BCAT1, BCAT2, PELP1 KMT2A 3415/4885KDM4E 3586/4885MAPT 1809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.